About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group aims to unravel the molecular mechanisms of cancer progression and metastasis to identify new diagnostic, prognostic and therapeutic targets in cancer. By combining the knowledge and availability of human tumors in the Pathology department with the expertise of the basic molecular cell biology research group, we focus on:
IP: Matilde Lleonart Pajarin Collaborators: Irene Braña Garcia, Yoelsis Garcia Mayea, Jordi Temprana Salvador, Angel García Jiménez, Sergio Benavente Norza, Josep Castellví Vives, Laia Josa Culleré, Marina Bataller Fernández Funding agency: Instituto de Salud Carlos III Funding: 183920 Reference: PI20/00556 Duration: 01/01/2021 - 30/06/2025
IP: Juan Angel Recio Conde Collaborators: Paula Granado Martinez, Kimberley Anne McGrail Fernández, Vicente García-Patos Briones, Berta Ferrer Fábrega, Sara Garcia Ortega, Eva Muñoz Couselo Funding agency: Instituto de Salud Carlos III Funding: 341220 Reference: PI20/00384 Duration: 01/01/2021 - 30/04/2024
IP: Maria Mar Hernandez Guillamon Collaborators: Jessica Camacho Soriano, Olga Maisterra Santos, Olalla Pancorbo Rosal Funding agency: Instituto de Salud Carlos III Funding: 169400 Reference: PI20/00465 Duration: 01/01/2021 - 30/06/2025
IP: Trond Aasen Collaborators: Maria Rosa Somoza Lopez de Haro, Jordi Temprana Salvador, Teresa Moline Marimon, Marta Sese Faustino, Irene Sansano Valero, Stefan Hummer Funding agency: Instituto de Salud Carlos III Funding: 147620 Reference: PI21/00470 Duration: 01/01/2022 - 30/06/2026
The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.
The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
Check the current rates for the services offered by the Translational Molecular Pathology research group.
Current Rates
PDF 0.25 MB
Rates Anatomia Patologica VHIR 2021
PDF 0.22 MB
